Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

NCT06150417 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.

NCT NCT06150417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06150417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Metastasis-directed Radiotherapy (MDRT) for Men With De-novo Oligometastatic Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Lead sponsor
Case Comprehensive Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2024
Completion date
December 1, 2028
Enrollment
200 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm of prostate, prostate cancer, secondary malignant neoplasm of prostate